PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SMMT vs. VKTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SMMT and VKTX is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

SMMT vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Summit Therapeutics Inc. (SMMT) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

0.00%200.00%400.00%600.00%800.00%OctoberNovemberDecember2025FebruaryMarch
84.34%
231.81%
SMMT
VKTX

Key characteristics

Sharpe Ratio

SMMT:

1.09

VKTX:

-0.81

Sortino Ratio

SMMT:

4.83

VKTX:

-1.33

Omega Ratio

SMMT:

1.60

VKTX:

0.84

Calmar Ratio

SMMT:

3.81

VKTX:

-0.94

Martin Ratio

SMMT:

10.86

VKTX:

-1.67

Ulcer Index

SMMT:

29.83%

VKTX:

41.01%

Daily Std Dev

SMMT:

297.46%

VKTX:

84.86%

Max Drawdown

SMMT:

-95.75%

VKTX:

-90.41%

Current Drawdown

SMMT:

-40.53%

VKTX:

-69.65%

Fundamentals

Market Cap

SMMT:

$14.01B

VKTX:

$3.22B

EPS

SMMT:

-$0.31

VKTX:

-$1.01

PEG Ratio

SMMT:

0.00

VKTX:

-0.03

Total Revenue (TTM)

SMMT:

$0.00

VKTX:

$0.00

Gross Profit (TTM)

SMMT:

-$67.00K

VKTX:

-$236.00K

EBITDA (TTM)

SMMT:

-$212.62M

VKTX:

-$150.74M

Returns By Period

In the year-to-date period, SMMT achieves a 6.42% return, which is significantly higher than VKTX's -28.73% return.


SMMT

YTD

6.42%

1M

-7.90%

6M

51.92%

1Y

292.36%

5Y*

63.26%

10Y*

6.08%

VKTX

YTD

-28.73%

1M

-11.40%

6M

-48.22%

1Y

-68.55%

5Y*

37.81%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SMMT vs. VKTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SMMT
The Risk-Adjusted Performance Rank of SMMT is 9494
Overall Rank
The Sharpe Ratio Rank of SMMT is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of SMMT is 9898
Sortino Ratio Rank
The Omega Ratio Rank of SMMT is 9797
Omega Ratio Rank
The Calmar Ratio Rank of SMMT is 9797
Calmar Ratio Rank
The Martin Ratio Rank of SMMT is 9494
Martin Ratio Rank

VKTX
The Risk-Adjusted Performance Rank of VKTX is 66
Overall Rank
The Sharpe Ratio Rank of VKTX is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of VKTX is 88
Sortino Ratio Rank
The Omega Ratio Rank of VKTX is 99
Omega Ratio Rank
The Calmar Ratio Rank of VKTX is 22
Calmar Ratio Rank
The Martin Ratio Rank of VKTX is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SMMT vs. VKTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SMMT, currently valued at 1.17, compared to the broader market-3.00-2.00-1.000.001.002.003.001.17-0.64
The chart of Sortino ratio for SMMT, currently valued at 4.90, compared to the broader market-4.00-2.000.002.004.004.90-0.75
The chart of Omega ratio for SMMT, currently valued at 1.62, compared to the broader market0.501.001.502.001.620.91
The chart of Calmar ratio for SMMT, currently valued at 4.07, compared to the broader market0.001.002.003.004.005.004.07-0.73
The chart of Martin ratio for SMMT, currently valued at 11.61, compared to the broader market0.005.0010.0015.0020.0011.61-1.43
SMMT
VKTX

The current SMMT Sharpe Ratio is 1.09, which is higher than the VKTX Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of SMMT and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00OctoberNovemberDecember2025FebruaryMarch
1.17
-0.64
SMMT
VKTX

Dividends

SMMT vs. VKTX - Dividend Comparison

Neither SMMT nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SMMT vs. VKTX - Drawdown Comparison

The maximum SMMT drawdown since its inception was -95.75%, which is greater than VKTX's maximum drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for SMMT and VKTX. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2025FebruaryMarch
-39.90%
-68.54%
SMMT
VKTX

Volatility

SMMT vs. VKTX - Volatility Comparison

Summit Therapeutics Inc. (SMMT) and Viking Therapeutics, Inc. (VKTX) have volatilities of 28.88% and 29.59%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%OctoberNovemberDecember2025FebruaryMarch
28.88%
29.59%
SMMT
VKTX

Financials

SMMT vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Summit Therapeutics Inc. and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab